Form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis - British Columbia, Canada

Form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis - British Columbia, Canada is a form used for requesting special authorization for the medication Natalizumab (Tysabri) to treat Multiple Sclerosis in the province of British Columbia, Canada.

The form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis in British Columbia, Canada is typically filed by the patient's prescribing physician or healthcare provider.

FAQ

Q: What is HLTH5385 Pharmacare Special Authority Request?
A: HLTH5385 Pharmacare Special Authority Request is a form used in British Columbia, Canada to request special authorization for the medication Natalizumab (Tysabri) for Multiple Sclerosis.

Q: What is Natalizumab (Tysabri)?
A: Natalizumab (Tysabri) is a medication used to treat Multiple Sclerosis.

Q: Who can use the HLTH5385 form?
A: The HLTH5385 form can be used by residents of British Columbia, Canada who require special authorization for Natalizumab (Tysabri) for the treatment of Multiple Sclerosis.

Q: How can I obtain the HLTH5385 form?
A: The HLTH5385 form can be obtained from healthcare providers or the British Columbia Ministry of Health.

Q: What is the purpose of the Special Authority Request?
A: The purpose of the Special Authority Request is to seek approval for coverage of Natalizumab (Tysabri) through the Pharmacare program for the treatment of Multiple Sclerosis.

Q: What information is required on the HLTH5385 form?
A: The HLTH5385 form requires information about the patient, prescriber, and the medical necessity for the use of Natalizumab (Tysabri) in treating Multiple Sclerosis.